Cargando…
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) reduce the need for red blood cell transfusions; however, they increase the risk of thromboembolic events and mortality. The impact of ESAs on quality of life (QoL) is controversial and led to different recommendations of medical societies and aut...
Autores principales: | Bohlius, J, Tonia, T, Nüesch, E, Jüni, P, Fey, M F, Egger, M, Bernhard, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090721/ https://www.ncbi.nlm.nih.gov/pubmed/24743705 http://dx.doi.org/10.1038/bjc.2014.171 |
Ejemplares similares
-
Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients
por: Rohner, Eliane, et al.
Publicado: (2017) -
Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece
por: Nikolaidi, Eleftheria, et al.
Publicado: (2013) -
Combination treatment with an erythropoiesis-stimulating agent and intravenous iron alleviates anaemia in patients with hereditary haemorrhagic telangiectasia
por: Cherif, Honar, et al.
Publicado: (2014) -
Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
por: Darsonval, Astrid, et al.
Publicado: (2017) -
Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia: protocol for a scoping review
por: Devlin, Paula, et al.
Publicado: (2022)